Short answer
Immunome Inc. (IMNM) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results for quarter ended September 30, 2026 announced.
Immunome Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results for quarter ended September 30, 2026 announced
- Business update included alongside quarterly financial results
- Investor-relevant figures and outlook available in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 net loss $85.8M, with operating expenses $90.4M versus $60.1M year over year
- Cash, equivalents and marketable securities $461.6M, expected to fund operations into 2028
- Varegacestat FDA decision targeted April 28, 2027, while EMA validated its marketing application
- IM-1021 showed 53% objective response rate in B-NHL, including five complete responses among 19 evaluable patients
- Pipeline expansion: IM-1340 IND cleared, Phase 1 expected by year-end 2026; updated IM-1021 data due December 14
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Immunome Inc. 8-K filings
Get the next IMNM 8-K as it lands
Follow IMNM for push alerts, or ask the research agent what this filing means.